| TA119 |
Leukaemia (lymphocytic) - fludarabine (TA119) |
|
-
-
Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Fludarabine given on its own is not recommended as an initial treatment for people with chronic lymphocytic leukaemia (CLL). Fludarabine is not licensed to be prescribed for CLL in combination with other chemotherapy medicines. This is because its 'marketing authorisation', which is normally needed before a drug can be prescribed, did not cover combination treatment. NICE was therefore unable to look at fludarabine in combination with other chemotherapy drugs for people with CLL. The process of giving a drug its marketing authorisation is not related to the NICE appraisal process and it is not carried out by NICE.
-
Other information
How this guidance was produced
Background information
This page was last updated: 06 April 2011
-
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
